# Top 10 population extracts from lung_kras_EN_cleaned.json

=== Ranked Population 1 (Extract #16, Adults) — Score: 8 ===
, single-arm trial © NICE 2024. All rights reserved. Subject to Notice of rights
small
apy,
mpar
cer
ed
n,
us
at
y,
0, a
and-
, so
rators
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-s
CodeBreaK100 trial. This is a phase 2, single-arm, multicentre, open lab
trial in 250 adults with KRAS G12C mutation-positive advanced tumours
126 participants had NSCLC. People in the trial previously had 1 (43%),
(35%) or 3 lines (22%) of anticancer therapy, measurable disease per
RECIST 1.1 criteria and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1. Most peop

=== Ranked Population 2 (Extract #17, Participants) — Score: 8 ===
to Notice of rights
small
apy,
mpar
cer
ed
n,
us
at
y,
0, a
and-
, so
rators
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-s
CodeBreaK100 trial. This is a phase 2, single-arm, multicentre, open lab
trial in 250 adults with KRAS G12C mutation-positive advanced tumours
126 participants had NSCLC. People in the trial previously had 1 (43%),
(35%) or 3 lines (22%) of anticancer therapy, measurable disease per
RECIST 1.1 criteria and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1. Most people (90%) had previously had
platinum-doublet chemotherapy (see sect

=== Ranked Population 3 (Extract #11, Patients) — Score: 7 ===
he Cancer Drugs Fund may resolve some
uncertainty in the clinical evidence. So, sotorasib is recommended for use in the Cancer
Drugs Fund.
© NICE 2024. All rights reserved. Subject to Notice of rights  Page 4 of 2.1 Sotorasib (Lumykras, Amgen) is indicated 'as monotherapy for the
treatment of adult patients with KRAS G12C-mutated locally advanced or
metastatic non-small-cell lung cancer (NSCLC), who have progressed on,
or are intolerant to, platinum-based chemotherapy and/or anti-PD-1/
PD-L1 immunotherapy'. 2.2 The dosage schedule is available in the summary of product
characteristics for sotorasib. 2

=== Ranked Population 4 (Extract #1, Population) — Score: 3 ===
ent associated with adverse
effects that affect health-related quality of life. The clinical expert
highlighted that people with KRAS G12C mutation-positive NSCLC have a
poor prognosis. The clinical and patient experts noted that there is an
unmet need for effective and tolerable treatments in this population.
They also highlighted that the lack of targeted treatment options can
have a psychological impact. This condition is associated with difficult-
to-treat symptoms, and the patient expert submission emphasised the
psychological impact of these on patients and their carers. The clinical
and patient e

=== Ranked Population 5 (Extract #8, Patients) — Score: 3 ===
recommendations in this guidance represent the view of NICE, arrived at after careful
consideration of the evidence available. When exercising their judgement, health
professionals are expected to take this guidance fully into account, alongside the
individual needs, preferences and values of their patients. The application of the
recommendations in this guidance is at the discretion of health professionals and their
individual patients and do not override the responsibility of healthcare professionals to
make decisions appropriate to the circumstances of the individual patient, in consultation
with t

=== Ranked Population 6 (Extract #9, Patients) — Score: 3 ===
exercising their judgement, health
professionals are expected to take this guidance fully into account, alongside the
individual needs, preferences and values of their patients. The application of the
recommendations in this guidance is at the discretion of health professionals and their
individual patients and do not override the responsibility of healthcare professionals to
make decisions appropriate to the circumstances of the individual patient, in consultation
with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment

=== Ranked Population 7 (Extract #12, Patients) — Score: 3 ===
effective and tolerable treatments in this population.
They also highlighted that the lack of targeted treatment options can
have a psychological impact. This condition is associated with difficult-
to-treat symptoms, and the patient expert submission emphasised the
psychological impact of these on patients and their carers. The clinical
and patient experts stated that a targeted treatment for the KRAS G12C
mutation in NSCLC would be welcomed. The committee concluded that
there is an unmet need for targeted treatments for KRAS G12C mutation-
positive locally advanced or metastatic NSCLC, and that thes

=== Ranked Population 8 (Extract #13, Patients) — Score: 3 ===
ment, it should be available for use, in line with NICE's
recommendations and the Cancer Drugs Fund criteria in the managed
access agreement. Further information can be found in NHS England's
Appraisal and funding of cancer drugs from July 2016 (including the new
Cancer Drugs Fund) – A new deal for patients, taxpayers and industry.
4.2 Chapter 2 of Appraisal and funding of cancer drugs from July 2016
(including the new Cancer Drugs Fund) – A new deal for patients,
taxpayers and industry states that for those drugs with a draft
recommendation for use in the Cancer Drugs Fund, interim funding will
be av

=== Ranked Population 9 (Extract #14, Patients) — Score: 3 ===
on can be found in NHS England's
Appraisal and funding of cancer drugs from July 2016 (including the new
Cancer Drugs Fund) – A new deal for patients, taxpayers and industry.
4.2 Chapter 2 of Appraisal and funding of cancer drugs from July 2016
(including the new Cancer Drugs Fund) – A new deal for patients,
taxpayers and industry states that for those drugs with a draft
recommendation for use in the Cancer Drugs Fund, interim funding will
be available (from the overall Cancer Drugs Fund budget) from the point
of marketing authorisation, or from release of positive draft guidance,
whichever is later.

=== Ranked Population 10 (Extract #2, Population) — Score: 2 ===
etaxel or docetaxel plus nintedanib
may be offered if the disease progresses. The clinical lead for the Canc
Drugs Fund highlighted that of all people with untreated locally advance
or metastatic NSCLC who have immunotherapy, about 40% have
immunotherapy alone rather than with chemotherapy. In this population
platinum-doublet chemotherapy would be offered at disease
progression, or through a clinical trial, before docetaxel or docetaxel plu
nintedanib is considered. In its submission, the company chose to only
compare sotorasib with docetaxel and docetaxel plus nintedanib. No
evidence was provided to co

